Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity. Issue 1 (22nd September 2021)

• Record Type: Journal Article
• Authors: Omer, Nurit; Giladi, Nir; Gurevich, Tanya; Bar‐Shira, Anat; Gana‐Weisz, Mali; Glinka, Tal; Goldstein, Orly; Kestenbaum, Meir; Cedarbaum, Jesse M.; Mabrouk, Omar S.; Fraser, Kyle B.; Shirvan, Julia C.; Orr‐Urtreger, Avi; Mirelman, Anat; Thaler, Avner
• Is Part Of: Movement disorders. Volume 37:Issue 1(2022)
• Page Start: 190
• Page End: 195
• Publication Date: 2021-09-22
• Subjects: Parkinson's disease -- LRRK2 -- GBA -- GCase; Movement disorders -- Periodicals; 610
• DOI: 10.1002/mds.28792
• Languages: English
• ISSNs: 0885-3185

Abstract

ABSTRACT: Background: Mutations in the GBA gene, which encodes the lysosomal enzyme glucocerebrosidase (GCase), are risk factors for Parkinson's disease (PD). Objective: To explore the association between GCase activity, PD phenotype, and probability for prodromal PD among carriers of mutations in the GBA and LRRK2 genes. Methods: Participants were genotyped for the G2019S‐ LRRK2 and nine GBA mutations common in Ashkenazi Jews. Performance‐based measures enabling the calculation of the Movement Disorder Society (MDS) prodromal probability score were collected. Results: One hundred and seventy PD patients (102 GBA ‐PD, 38 LRRK2 ‐PD, and 30 idiopathic PD) and 221 non‐manifesting carriers (NMC) (129 GBA ‐NMC, 45 LRRK2 ‐NMC, 15 GBA ‐ LRRK2 ‐NMC, and 32 healthy controls) participated in this study. GCase activity was lower among GBA ‐PD (3.15 ± 0.85 μmol/L/h), GBA ‐NMC (3.23 ± 0.91 μmol/L/h), and GBA ‐ LRRK2 ‐NMC (3.20 ± 0.93 μmol/L/h) compared to the other groups of participants, with no correlation to clinical phenotype. Conclusions: Low GCase activity does not explain the clinical phenotype or risk for prodromal PD in this cohort. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society